Learn More
OBJECTIVES To assess the long-term safety and efficacy of dutasteride, a dual type 1 and type 2 5-alpha-reductase inhibitor, in the treatment of symptomatic benign prostatic hyperplasia and associated lower urinary tract symptoms. METHODS Data from two Phase IIIa multicenter, randomized, placebo-controlled trials of 2-year duration plus a 2-year(More)
  • 1